SITC Resource Library

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

09-27-2017 09:45

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article that hypothesized that DRR is an appropriate measure of the ability of immunotherapy anticancer agents to mediate a clinically meaningful, sustained reduction in tumor burden that may be associated with measures of clinical benefit such as prolonged overall survival (OS), improved quality of life (QoL), and freedom from successive anticancer therapies. Authors: Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross JITC(2017) 5:72

#Article #Advanced #ClinicalTrials #TherapeuticCancerVaccines #Researcher #JITCPublication #SkinCancer #2017

Statistics
0 Favorited
4 Views
0 Files
0 Shares
0 Downloads

Tags and Keywords

Related Entries and Links

No Related Resource entered.